311-21-7 Usage
Uses
Used in Pharmaceutical Industry:
3-oxa-9-azaspiro[5.5]undecane (SALTDATA: FREE) is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the formation of complex molecular structures that can possess specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 3-oxa-9-azaspiro[5.5]undecane (SALTDATA: FREE) serves as a crucial building block for creating a wide array of organic compounds, leveraging its unique spiro-structure to facilitate the development of new chemical entities with potential applications in various industries.
Used in Material Science:
3-oxa-9-azaspiro[5.5]undecane (SALTDATA: FREE) is utilized in material science as a component in the development of new materials, taking advantage of its molecular structure to enhance or impart specific characteristics to these materials, such as improved stability or reactivity.
Used in Research and Development:
As a free chemical, 3-oxa-9-azaspiro[5.5]undecane (SALTDATA: FREE) is extensively used in research and development settings to explore its potential in various chemical reactions and to innovate new methods for its synthesis and application, further expanding its utility in science and industry.
Check Digit Verification of cas no
The CAS Registry Mumber 311-21-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,1 and 1 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 311-21:
(5*3)+(4*1)+(3*1)+(2*2)+(1*1)=27
27 % 10 = 7
So 311-21-7 is a valid CAS Registry Number.
311-21-7Relevant academic research and scientific papers
PD-1/PD-L1 small molecule inhibitor and application thereof in medicines
-
Paragraph 0822; 0825-0827, (2020/11/02)
The invention belongs to the field of medicines, and relates to a PD-1/PD-L1 small molecule inhibitor and application thereof in medicines. Specifically, the invention provides a PD-1/PD-L1 small molecule inhibitor, which is a compound shown as a formula (I), or a stereoisomer, a geometrical isomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, ester, pharmaceutically acceptable salt orprodrug of the compound shown as the formula (I). The invention further provides a preparation method of the compound shown in the formula (I), a pharmaceutical composition containing the compound shown in the formula (I) and application of the compound and the pharmaceutical composition in the preparation of drugs for preventing or treating diseases related with PD-1/PD-L1 signaling pathways.
